Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.

[1]  Derek S. Tan,et al.  Host Interactions with Engineered T-cell Micropharmacies , 2023, Cancer immunology research.

[2]  K. Janeway,et al.  A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high‐dose methotrexate therapy in open‐label trials , 2023, Pediatric blood & cancer.

[3]  P. Turnbaugh,et al.  SIMMER employs similarity algorithms to accurately identify human gut microbiome species and enzymes capable of known chemical transformations , 2023, eLife.

[4]  S. Tolaney,et al.  Optimizing the safety of antibody–drug conjugates for patients with solid tumours , 2023, Nature Reviews Clinical Oncology.

[5]  M. Burns,et al.  Pharmaceutical Purchasing: a Review of the Landscape and Implications for Antidotal Therapies , 2023, Journal of Medical Toxicology.

[6]  Tinghe Yu,et al.  Development of ZD2767P–carboxypeptidase G2–ultrasound therapy against cisplatin-resistant cancer , 2023, Frontiers in Oncology.

[7]  S. Yao,et al.  The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. , 2023, Chemical reviews.

[8]  A. V. von Bueren,et al.  Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023? , 2023, Frontiers in Pharmacology.

[9]  H. Kawamoto,et al.  Pharmacokinetics and Pharmacodynamics of Glucarpidase Rescue Treatment After High-dose Methotrexate Therapy Based on Modeling and Simulation , 2023, AntiCancer Research.

[10]  Yifei Guo,et al.  Effects of different conformations of polylysine on the anti-tumor efficacy of methotrexate nanoparticles. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  S. Suresh,et al.  Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity , 2023, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[12]  Y. Chen,et al.  External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. , 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  M. Liu,et al.  Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context , 2023, Advanced science.

[14]  H. Yokoi,et al.  Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists , 2023, International Journal of Clinical Oncology.

[15]  S. Ward,et al.  Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis , 2023, ClinicoEconomics and outcomes research : CEOR.

[16]  P. Schaiquevich,et al.  A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma , 2023, Cancers.

[17]  M. Scheurer,et al.  Novel and replicated clinical and genetic risk factors for toxicity from high‐dose methotrexate in pediatric acute lymphoblastic leukemia , 2023, Pharmacotherapy.

[18]  R. Arbel,et al.  Real-world effectiveness of a single dose of mpox vaccine in males , 2023, Nature Medicine.

[19]  Austin L. Brown,et al.  Ethnic‐specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high‐dose methotrexate , 2023, Cancer.

[20]  K. Bose,et al.  Purification of hetero-oligomeric protein variants using a modified tandem affinity purification approach , 2023, STAR protocols.

[21]  M. Zanoni,et al.  Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota , 2023, Frontiers in Cell and Developmental Biology.

[22]  K. Knipping,et al.  Critical features of an in vitro intestinal absorption model to study the first key aspects underlying food allergen sensitization. , 2022, Comprehensive reviews in food science and food safety.

[23]  S. Hemmati,et al.  Polypharmacological Cell-Penetrating Peptides from Venomous Marine Animals Based on Immunomodulating, Antimicrobial, and Anticancer Properties , 2022, Marine drugs.

[24]  S. Amizadeh,et al.  In vitro and in silico characterization of a novel glutamate carboxypeptidase from Cohnella sp. A01. , 2022, Biochimie.

[25]  Yuan Luo,et al.  Ultrasonically Enhanced ZD2767P–Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells , 2022, Oxidative medicine and cellular longevity.

[26]  Chao-Yu Zhang,et al.  Optimization of the expression of the main protease from SARS-CoV-2 , 2022, Protein Expression and Purification.

[27]  Geun-Joong Kim,et al.  One-step metal affinity purification of recombinant hFGF19 without using tags. , 2022, Protein expression and purification.

[28]  Shibo Jiang,et al.  Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses , 2022, Nature Reviews Immunology.

[29]  R. Singh,et al.  β-galactosidase as an industrial enzyme: production and potential , 2022, Chemical Papers.

[30]  A. El-Sayed,et al.  Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy , 2022, Heliyon.

[31]  C. Stewart,et al.  CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children. , 2022, Drug metabolism and pharmacokinetics.

[32]  Max Jan,et al.  SEAKER cells coordinate cellular immunotherapy with localized chemotherapy. , 2022, Trends in pharmacological sciences.

[33]  L. Deangelis,et al.  Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study , 2022, BMC cancer.

[34]  M. Pepper,et al.  Equitable access to cell and gene therapies in South Africa: opportunities and hurdles , 2022, Gene Therapy.

[35]  Tal Danino,et al.  CAR-T cells SEAK help from enzymes , 2021, Nature Chemical Biology.

[36]  Derek S. Tan,et al.  Engineering CAR-T cells to activate small-molecule drugs in situ , 2021, Nature Chemical Biology.

[37]  M. Bornhäuser,et al.  Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury , 2021, Cancer Chemotherapy and Pharmacology.

[38]  L. Rus,et al.  Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy , 2021, Molecules.

[39]  Jamie B. Spangler,et al.  Engineered antibody fusion proteins for targeted disease therapy. , 2021, Trends in pharmacological sciences.

[40]  G. Ariceta,et al.  Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available , 2021, Frontiers in Pediatrics.

[41]  Y. Ghasemi,et al.  Whole cell immobilization of recombinant E. coli cells by calcium alginate beads; evaluation of plasmid stability and production of extracellular L-asparaginase , 2021, Separation Science and Technology.

[42]  Issa Sadeghian,et al.  Characterization of a Stable Form of Carboxypeptidase G2 (Glucarpidase), a Potential Biobetter Variant, From Acinetobacter sp. 263903-1 , 2021, Molecular Biotechnology.

[43]  Mohadeseh Safaei,et al.  A review on analytical methods with special reference to electroanalytical methods for the determination of some anticancer drugs in pharmaceutical and biological samples. , 2021, Talanta.

[44]  L. Pollegioni,et al.  An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin. , 2021, Nanomedicine : nanotechnology, biology, and medicine.

[45]  M. Scheurer,et al.  Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene , 2021, Pediatric blood & cancer.

[46]  Vitaliy Sazonov,et al.  New Therapeutic Approach to Reduce Methotrexate Toxicity after High-Dose Chemotherapy in a Child with Acute Lymphocytic Leukemia: Efficacy and Safety of Hemoadsorption with HA-230 Adsorber , 2021, Blood Purification.

[47]  B. V. Van Tine,et al.  Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies , 2021, Journal of clinical medicine.

[48]  J. Bulcha,et al.  Viral vector platforms within the gene therapy landscape , 2021, Signal Transduction and Targeted Therapy.

[49]  S. Asad,et al.  Enhanced Solubility and One-Step Purification of Functional Dimeric Carboxypeptidase G2 , 2021, Biochemistry. Biokhimiia.

[50]  M. Barker,et al.  Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site , 2021, Molecules.

[51]  N. Leung,et al.  Fixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series. , 2021, Clinical lymphoma, myeloma & leukemia.

[52]  P. Elsinga,et al.  Production of Long-Acting CNGRC–CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment , 2021, Technology in cancer research & treatment.

[53]  C. Récher,et al.  Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients , 2020, Leukemia and Lymphoma.

[54]  P. Elsinga,et al.  Production of active long lasting CNGRC-CPG2 Fusion Protein using PEGylation to be used in Ligand Directed Cancer Therapy , 2020 .

[55]  I. Krämer,et al.  Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[56]  Issa Sadeghian,et al.  Introducing a delivery system for melanogenesis inhibition in melanoma B16F10 cells mediated by the conjugation of tyrosine ammonia‐lyase and a TAT‐penetrating peptide , 2020, Biotechnology progress.

[57]  D. Scheinberg,et al.  Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery , 2020, Cancers.

[58]  J. Díez-Martín,et al.  A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults? , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[59]  Bcop,et al.  Monitoring Methotrexate Levels in a Patient After Glucarpidase Administration: A Case Report , 2020 .

[60]  S. Hemmati,et al.  Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors , 2020, Infection, Genetics and Evolution.

[61]  Ying Zhang,et al.  Ultrasound enhances ZD2767P‒carboxypeptidase G2 against chemoresistant ovarian cancer cells by altering the intracellular pharmacokinetics of ZD2767D. , 2020, Molecular Pharmaceutics.

[62]  A. Vinks,et al.  MTXPK.org: A Clinical Decision Support Tool Evaluating High‐Dose Methotrexate Pharmacokinetics to Inform Post‐Infusion Care and Use of Glucarpidase , 2020, medRxiv.

[63]  Lin Yang,et al.  Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis , 2020, Cancer Chemotherapy and Pharmacology.

[64]  J. Bouwstra,et al.  Glucocerebrosidase: Functions in and Beyond the Lysosome , 2020, Journal of clinical medicine.

[65]  Sayed K Goda,et al.  Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[66]  P. Elsinga,et al.  In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy , 2020, Oncotarget.

[67]  K. Khajeh,et al.  Cloning, expression and Characterization of Carboxypeptidase G2 Enzyme from E.coli , 2019 .

[68]  S. Hemmati,et al.  Considerations on the Rational Design of Covalently Conjugated Cell-Penetrating Peptides (CPPs) for Intracellular Delivery of Proteins: A Guide to CPP Selection Using Glucarpidase as the Model Cargo Molecule , 2019, Molecules.

[69]  H. Tajmir-Riahi,et al.  Biodegradable Polymers for Gene Delivery , 2019, Molecules.

[70]  K. Hoang-Xuan,et al.  P14.118 Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study , 2019, Neuro-Oncology.

[71]  S. Heil.  Genetics of high-dose methotrexate-induced oral mucositis: current perspectives. , 2019, Pharmacogenomics.

[72]  A. Tedesco,et al.  Prodrugs for targeted cancer therapy , 2019, Expert review of anticancer therapy.

[73]  C. O'Connor,et al.  Production of "biobetter" variants of glucarpidase with enhanced enzyme activity. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[74]  Y. Ghasemi,et al.  Identification and characterization of a sterically robust phenylalanine ammonia-lyase among 481 natural isoforms through association of in silico and in vitro studies. , 2019, Enzyme and microbial technology.

[75]  L. Koenig,et al.  Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study , 2019, ClinicoEconomics and outcomes research : CEOR.

[76]  P. Elsinga,et al.  Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[77]  B. Behera.  Biopharmaceuticals , 2018 .

[78]  T. Flægstad,et al.  Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2 , 2018, Pediatric hematology and oncology.

[79]  J. Schouten,et al.  Characterisation of the Carboxypeptidase G2 Catalytic Site and Design of New Inhibitors for Cancer Therapy , 2018, Chembiochem : a European journal of chemical biology.

[80]  R. Vohra,et al.  Working Through the Paradox of Methotrexate Toxicity. , 2018, Annals of emergency medicine.

[81]  R. Singh,et al.  Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. , 2018, European journal of medicinal chemistry.

[82]  Y. Ghasemi,et al.  TAT‐mediated intracellular delivery of carboxypeptidase G2 protects against methotrexate‐induced cell death in HepG2 cells , 2018, Toxicology and applied pharmacology.

[83]  A. Dömling,et al.  Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment , 2018, PloS one.

[84]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[85]  Kirk D. Wyatt,et al.  Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels , 2017, Journal of pediatric hematology/oncology.

[86]  Małgorzata Kęsik-Brodacka.  Progress in biopharmaceutical development , 2017, Biotechnology and applied biochemistry.

[87]  A. Bleyer,et al.  Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance , 2017, The oncologist.

[88]  Q. You,et al.  Prodrug strategy for cancer cell-specific targeting: A recent overview. , 2017, European journal of medicinal chemistry.

[89]  Y. Ghasemi,et al.  In silico Investigation of Pullulanase Enzymes from Various Bacillus Species , 2017 .

[90]  K. Schmiegelow,et al.  Delayed elimination of high‐dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia , 2017, Pediatric blood & cancer.

[91]  S. Khare,et al.  Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme , 2017, Protein engineering, design & selection : PEDS.

[92]  Fatih Uckaya,et al.  Chitosan and carboxymethyl cellulose based magnetic nanocomposites for application of peroxidase purification. , 2017, International journal of biological macromolecules.

[93]  Sur Sharma,et al.  Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination , 2017, Expert opinion on biological therapy.

[94]  J. Schouten,et al.  Soluble expression, purification and functional characterisation of carboxypeptidase G2 and its individual domains. , 2016, Protein expression and purification.

[95]  A. Hatefi,et al.  Enzyme/Prodrug Systems for Cancer Gene Therapy , 2016, Current Pharmacology Reports.

[96]  Z. Özdemir,et al.  The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate , 2016, International journal of pediatrics & adolescent medicine.

[97]  M. Sadelain.  Chimeric antigen receptors: driving immunology towards synthetic biology. , 2016, Current opinion in immunology.

[98]  C. K. Sahu,et al.  The 46 kDa dimeric protein from Variovorax paradoxus shows faster methotrexate degrading activity in its nanoform compare to the native enzyme. , 2016, Enzyme and microbial technology.

[99]  B. Widemann.  Practical considerations for the administration of glucarpidase in high‐dose methotrexate (HDMTX) induced renal dysfunction , 2015, Pediatric blood & cancer.

[100]  K. Horibe,et al.  Statistical analysis of relation between plasma methotrexate concentration and toxicity in high‐dose methotrexate therapy of childhood nonHodgkin lymphoma , 2015, Pediatric blood & cancer.

[101]  Tinghe Yu,et al.  Nanosecond electric pulses deprive zinc ions of carboxypeptidase G2. , 2015, Bioelectrochemistry.

[102]  R. de Jonge,et al.  Using Fluorescence Polarization Immunoassay for Determination of Erythrocyte Methotrexate Polyglutamates, a Quick and Easy Test? , 2014, Therapeutic drug monitoring.

[103]  Baojian Wu,et al.  Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns , 2014, Expert opinion on drug metabolism & toxicology.

[104]  C. Pui,et al.  Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High‐Dose Methotrexate Therapy , 2014, Pharmacotherapy.

[105]  Barry Byrne,et al.  Preparative Purification of Recombinant Proteins: Current Status and Future Trends , 2013, BioMed research international.

[106]  Mohammad A Rattu,et al.  Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. , 2013, P & T : a peer-reviewed journal for formulary management.

[107]  Philip S Low,et al.  Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors. , 2013, ACS nano.

[108]  A. Francisco,et al.  Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation. , 2012, Bioorganic & medicinal chemistry letters.

[109]  C. Thompson.  CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[110]  Tingyun Yang,et al.  Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[111]  Dennis J. Cada,et al.  Glucarpidase , 2012, Definitions.

[112]  J. Ritchie,et al.  Improved Sensitivity for Methotrexate Analysis Using Enzyme Multiplied Immunoassay Technique on the Siemens Viva-E Instrument , 2012, Therapeutic drug monitoring.

[113]  R. Qudsi,et al.  Low‐dose carboxypeptidase‐G2 for methotrexate toxicity in a child , 2010, Pediatric blood & cancer.

[114]  P. Adamson,et al.  Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  B. Cronstein,et al.  Methotrexate—how does it really work? , 2010, Nature Reviews Rheumatology.

[116]  Sayed K Goda,et al.  Functional Overexpression and Purification of a Codon Optimized Synthetic Glucarpidase (Carboxypeptidase G2) in Escherichia coli , 2009, The protein journal.

[117]  L. Goldfrank,et al.  Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. , 2009, Annals of emergency medicine.

[118]  Panos Lehouritis,et al.  Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy , 2008, Clinical Cancer Research.

[119]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[120]  M. Kuroki,et al.  Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan , 2008, Cancer Gene Therapy.

[121]  C. Springer,et al.  Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury , 2007, Nature Reviews Cancer.

[122]  Heide Kogelberg,et al.  Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. , 2007, Glycobiology.

[123]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[124]  C. Springer,et al.  Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. , 2007, Cancer research.

[125]  R. Begent,et al.  Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. , 2006, Bioorganic & medicinal chemistry letters.

[126]  S. Brocchini,et al.  Diethylstilbestrol glutamate as a potential substrate for ADEPT , 2006, Journal of drug targeting.

[127]  C. Springer,et al.  Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. , 2005, Journal of medicinal chemistry.

[128]  C. Springer,et al.  Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. , 2005, Cancer research.

[129]  G. Hempel,et al.  Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications , 2005, Cancer Chemotherapy and Pharmacology.

[130]  R. Begent,et al.  Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  R. Hermann,et al.  Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. , 2004, Journal of the National Cancer Institute.

[132]  S. Sharma,et al.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT) , 2004, British Journal of Cancer.

[133]  C. Springer,et al.  Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. , 2004, Journal of medicinal chemistry.

[134]  C. Springer,et al.  Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. , 2003, Journal of medicinal chemistry.

[135]  S. Emery,et al.  Adenovirus vector–mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane , 2002, Cancer Gene Therapy.

[136]  C. Springer,et al.  A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours , 2002, British Journal of Cancer.

[137]  N. Curtin,et al.  DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. , 2002, European journal of cancer.

[138]  C. Springer,et al.  Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. , 2002, Cancer research.

[139]  A. Rees,et al.  A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics , 2002, Proteomics.

[140]  N. Curtin,et al.  Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue , 2001, British Journal of Cancer.

[141]  C. Berkman,et al.  Stereoselective inhibition of glutamate carboxypeptidase by chiral phosphonothioic acids. , 2001, Bioorganic & medicinal chemistry.

[142]  R. Begent,et al.  Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer , 2000, Cancer Chemotherapy and Pharmacology.

[143]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  R. Begent,et al.  Catalytic activity of an in vivo tumor targeted anti‐CEA scFv::carboxypeptidase G2 fusion protein , 2000, International journal of cancer.

[145]  C. Springer,et al.  Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. , 1999, Cancer research.

[146]  D. Hochhauser,et al.  Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material , 1999, British Journal of Cancer.

[147]  C. Springer,et al.  Self-immolative anthracycline prodrugs for suicide gene therapy. , 1999, Journal of medicinal chemistry.

[148]  F. Searle,et al.  Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy. , 1999, Journal of medicinal chemistry.

[149]  C. Springer,et al.  Self-immolative nitrogen mustard prodrugs for suicide gene therapy. , 1998, Journal of medicinal chemistry.

[150]  C. Springer,et al.  A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy , 1997, Nature Biotechnology.

[151]  P. Brick,et al.  Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. , 1997, Structure.

[152]  S. Sharma,et al.  Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. , 1996, Transplantation proceedings.

[153]  A. Photiou,et al.  Antibody-directed enzyme prodrug therapy (ADEPT). , 1996, International journal of oncology.

[154]  C. Springer,et al.  ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. , 1996, Cancer research.

[155]  R. Begent,et al.  In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. , 1996, Immunotechnology : an international journal of immunological engineering.

[156]  C. Springer,et al.  Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). , 1995, Journal of medicinal chemistry.

[157]  S. Sharma,et al.  Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. , 1995, British Journal of Cancer.

[158]  P. Adamson,et al.  Carboxypeptidase‐G2 rescue in a patient with high dose methotrexate‐induced nephrotoxicity , 1995, Cancer.

[159]  C. Springer,et al.  Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. , 1994, British Journal of Cancer.

[160]  C. Springer,et al.  Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. , 1994, Cancer research.

[161]  I. Niculescu-Duvaz,et al.  Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. , 1994, Journal of medicinal chemistry.

[162]  C. Springer,et al.  Galactosylated antibodies and antibody‐enzyme conjugates in antibody‐directed enzyme prodrug therapy , 1994, Cancer.

[163]  W. Denny,et al.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) , 1993, Cancer and Metastasis Reviews.

[164]  J. Boyle,et al.  Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. , 1993, Journal of immunological methods.

[165]  R. Sherwood,et al.  Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial , 1992, Cell Biophysics.

[166]  P. Adamson,et al.  Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  C. Springer,et al.  Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. , 1991, European journal of cancer.

[168]  C. Springer,et al.  Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). , 1991, Anti-cancer drug design.

[169]  S. Sharma,et al.  Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. , 1990, British Journal of Cancer.

[170]  K. Bagshawe,et al.  The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model. , 1990, British Journal of Cancer.

[171]  C. Springer,et al.  Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. , 1990, Journal of medicinal chemistry.

[172]  R. Sherwood,et al.  Production of cloned carboxypeptidase G2 by Escherichia coli: Genetic and environmental considerations , 1989, Biotechnology Letters.

[173]  R. Sherwood,et al.  Plasmid pMTL153: a high copy number version of pAT153 and its use to obtain high expression of the Pseudomonas carboxypeptidase G2 gene , 1988, Applied Microbiology and Biotechnology.

[174]  C. Springer,et al.  A cytotoxic agent can be generated selectively at cancer sites. , 1988, British Journal of Cancer.

[175]  Christopher R. Lowe,et al.  Purification of proteins by aqueous two-phase partition in novel acrylic co-polymer systems , 1988 .

[176]  R. Buckley,et al.  The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. , 1986, British Journal of Cancer.

[177]  R. Melton,et al.  Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. , 1985, European journal of biochemistry.

[178]  R. Sherwood,et al.  Expression of the Pseudomonas gene coding for carboxypeptidase G2 in Saccharomyces cerevisiae. , 1985, Journal of general microbiology.

[179]  T. Atkinson,et al.  Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida , 1983, Journal of bacteriology.

[180]  C. Lowe,et al.  Metal ion-promoted binding of proteins to immobilized triazine dye affinity adsorbents. , 1982, Biochimica et biophysica acta.

[181]  T. Atkinson,et al.  High-performance liquid affinity chromatography of enzymes on silica-immobilised triazine dyes , 1981 .

[182]  Issa Sadeghian,et al.  Biochemical insights into a novel thermo/organo tolerant bilirubin oxidase from Thermosediminibacter oceani and its application in dye decolorization , 2020 .

[183]  Hui Chin Goh,et al.  Going native: Complete removal of protein purification affinity tags by simple modification of existing tags and proteases. , 2017, Protein expression and purification.

[184]  Y. Ghasemi,et al.  Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme. , 2015, Current pharmaceutical biotechnology.

[185]  Mingnan Chen,et al.  Gene-Directed Enzyme Prodrug Therapy , 2014, The AAPS Journal.

[186]  A. Ali,et al.  scFv Antibody: Principles and Clinical Application , 2012, Clinical & developmental immunology.

[187]  C. Springer,et al.  Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug , 2009, Cell Biophysics.

[188]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy (ADEPT) , 2007, Cell Biophysics.

[189]  C. Springer,et al.  Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft , 1997, Cancer Chemotherapy and Pharmacology.

[190]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial , 1997, Cancer Chemotherapy and Pharmacology.

[191]  R. Melton,et al.  Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. , 1993, European journal of cancer.

[192]  R. Melton,et al.  Covalent linkage of carboxypeptidase G2 to soluble dextrans--I. Properties of conjugates and effects on plasma persistence in mice. , 1987, Biochemical pharmacology.